Cogstate Releases Online Cognitive Screening Solution for Alzheimer's Trial
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments
Cogstate, a cognitive science and medical technology company, announced the latest version of its remote cognitive assessment solution for pre-screening participants in clinical trials, Precision Recruitment™ 2.1.
This new version release optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments. Other important new features include:
- Functionality allowing pre-screened participants to select an investigator site in their area, with automatic site notification for a more seamless enrolment process.
- The ability to deploy the solution in many different languages, as required for global clinical trials
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
